
The following summarizes the components of Identifiable intangible assets:
	June 28, 2026						December 31, 2025
(MILLIONS)	Gross Carrying Amount		Accumulated Amortization		Identifiable Intangible Assets, Net		Gross Carrying Amount		Accumulated Amortization		Identifiable Intangible Assets, Net
Finite-lived intangible assets
Developed technology rights(a)	$	100,799	$	(72,512)	$	28,287	$	100,630	$	(70,172)	$	30,458
Brands	1,035		(1,035)		—		1,035		(1,035)		—
Licensing agreements and other	2,364		(1,378)		986		2,341		(1,289)		1,052

	104,198		(74,925)		29,273		104,006		(72,496)		31,510
Indefinite-lived intangible assets

IPR&D(a)	17,320				17,320		21,760				21,760
Licensing agreements and other	460				460		460				460
	17,780				17,780		22,221				22,221
Identifiable intangible assets	$	121,978	$	(74,925)	$	47,053	$	126,227	$	(72,496)	$	53,731

(a)The gross carrying amounts as of June 28, 2026 reflect impairments of $3.8 billion in IPR&D assets and $525 million in developed technology rights (see Note 4). The gross carrying amounts also reflect a transfer of $580 million from IPR&D to developed technology rights for Tukysa (tucatinib).

As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2026 (see Note 13A), our goodwill is required to be reallocated amongst impacted reporting units. The reallocation of goodwill is a complex process that requires, among other things, determination of the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. The reallocation will be completed in the current fiscal year. All goodwill continues to be assigned within the Biopharma reportable segment.